● Outset reported second-quarter 2026Revenueof about $31.6 million in results that reporting described as mixed.
● The company lowered its full-year U.S. Omnipod outlook, citing challenges including retention among type 2 diabetes patients.
● The company reported second-quarter 2026 results in early August 2026 showing Auryxia sales declining while Vafseo gained traction.
BioAtla (NASDAQ:BCAB) has reached a difficult crossroads common to clinical-stage biotechs that run low on the market's patience and their own capital. The developer of conditionally active biologic therapies has launched a formal process to evaluate strategic options for monetizing its assets, a step …
DocGo (NASDAQ:DCGO) is working to reposition itself as a broader healthcare-services company. The mobile-health and medical-transportation provider reported second-quarter 2026 results that paired record patient volumes with a guidance cut, and it announced an acquisition intended to expand its virtual-care capabilities.
aTyr Pharma (NASDAQ:ATYR) has made a decisive, high-risk choice: shrink the company dramatically to concentrate its resources on a single lead drug and the regulatory decisions that will define its future. The clinical-stage biotech announced a sweeping restructuring in August 2026 as it doubles …
● CEL-SCI announced plans to launch an FDA registration-enabling Phase 3 confirmatory study for Multikine, with reporting pointing to a study of roughly 212 patients.
●Phase 3 miss:On February 23, 2026, Gossamer announced that the Phase 3 PROSERA study of seralutinib did not meet its primary endpoint with statistical significance.
● ImageneBio's lead program, IMG-007, is an antibody being developed for atopic dermatitis and potentially other immune-mediated diseases.
Seres Therapeutics (NASDAQ:MCRB) is a pioneer in the emerging field of live biotherapeutic products, medicines made from communities of bacteria, now concentrating its efforts on a candidate designed to prevent dangerous infections in vulnerable patients. The company is balancing promising clinical data against a …